1-(4-chlorophenylhydrazono)-1-(4-ethynylphenylamino)-3,3-dimethyl-2-butanone | 934370-19-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-(4-chlorophenylhydrazono)-1-(4-ethynylphenylamino)-3,3-dimethyl-2-butanone
• 英文别名: N-(4-chloroanilino)-N'-(4-ethynylphenyl)-3,3-dimethyl-2-oxobutanimidamide
• CAS: 934370-19-1
• 化学式: C₂₀H₂₀ClN₃O
• 分子量: 353.851
• InChiKey: PTWXJWWMGVIDIR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6
• 重原子数：
  25
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  53.5
• 氢给体数：
  2
• 氢受体数：
  3

文献信息

• S1P3 RECEPTOR ANTAGONIST
  申请人：Ohnuma Shin-ya

  公开号：US20090170895A1

  公开（公告）日：2009-07-02

  The present invention relates to a medicine, and more particularly to novel arylamidrazone derivatives having an antagonistic action against S1P 3 receptors and a medicine containing thereof as an active ingredient. The present invention provides an arylamidrazone derivative represented by the following formula (1) or a pharmaceutically acceptable salt thereof: wherein R 1 represents a C 2 -C 8 alkyl group which may be substituted, a phenyl group which may be substituted, an aromatic heterocyclic group which may be substituted, a C 2 -C 8 alkoxy group which may be substituted, or —NR 4 R 5 (wherein R 4 and R 5 , which are identical or different, each represent a hydrogen atom or a lower alkyl group which may be substituted, or R 4 and R 5 may be joined with the adjacent nitrogen atom to form a nitrogen-containing heterocyclic ring which may be substituted); R 2 and R 3 , which are identical or different, each represent a hydrogen atom, a halogen atom, a halo-lower alkyl group, a lower alkyl group, a lower alkynyl group, a lower alkoxy group, a cyano group, a lower alkanoyl group or a lower alkylsulfonyl group; A represents a benzene ring or a heterocyclic ring; D represents a single bond or methylene; m represents an integer from 1 to 3, and n represents an integer from 1 to 5 (with the proviso that the case where R 1 is an ethoxy group, R 2 is a 2,4-dichloro group, R 3 is a hydrogen atom, A is a benzene ring, and D is methylene; and the case where R 1 is an ethoxy group, R 2 is a 2,4-dichloro group, R 3 is a hydrogen atom, a 2-methyl group, a 4-methyl group, a 4-methoxy group or a 4-ethoxy group, A is a benzene ring, and D is a single bond, are excluded).

  本发明涉及一种药物，更具体地涉及一种对S1P3受体具有拮抗作用的新型芳基酰胺脲衍生物及其作为活性成分的药物。本发明提供了下式（1）或其药学上可接受的盐所表示的芳基酰胺脲衍生物：其中R1表示可取代的C2-C8烷基，可取代的苯基，可取代的芳香杂环基，可取代的C2-C8烷氧基，或—NR4R5（其中R4和R5相同或不同，每个代表氢原子或可取代的低烷基，或R4和R5可以与相邻的氮原子连接形成可取代的含氮杂环环，其中R4和R5的情况下，它们相邻的氮原子可以连接形成可取代的含氮杂环环）；R2和R3相同或不同，每个代表氢原子，卤原子，卤代低烷基，低烷基，低炔基，低烷氧基，氰基，低烷酰基或低烷基磺酰基；A代表苯环或杂环环；D代表单键或亚甲基；m表示1到3的整数，n表示1到5的整数（但其中R1为乙氧基，R2为2,4-二氯基，R3为氢原子，A为苯环，D为亚甲基的情况和R1为乙氧基，R2为2,4-二氯基，R3为氢原子，2-甲基，4-甲基，4-甲氧基或4-乙氧基，A为苯环，D为单键的情况不包括在内）。
• TY-52156 COMPOUNDS FOR THE TREATMENT OF CANCER
  申请人：WAYNE STATE UNIVERSITY

  公开号：US20190117596A1

  公开（公告）日：2019-04-25

  TY-52156 compounds for the treatment of lung cancers and cancers mediated by KRAS gene mutations and/or TGF-β/Smad3 signaling are described. TY-52156 compounds antagonize sphingosine-1-phosphate receptor subtype 3 (S1PR3). Methods and kits for selecting subjects for particular treatments and/or clinical trials are also described.
• US8546452B2
  申请人：——

  公开号：US8546452B2

  公开（公告）日：2013-10-01
• [EN] TY-52156 COMPOUNDS FOR THE TREATMENT OF CANCER<br/>[FR] COMPOSÉS DE TY-5215 POUR LE TRAITEMENT DU CANCER
  申请人：UNIV WAYNE STATE

  公开号：WO2017190077A1

  公开（公告）日：2017-11-02

  TY-52156 compounds for the treatment of lung cancers and cancers mediated by KRAS gene mutations and/or TGF-β/Smad3 signaling are described. TY-52156 compounds antagonize sphingosine-1-phosphate receptor subtype 3 (S1PR3). Methods and kits for selecting subjects for particular treatments and/or clinical trials are also described.